Clinical Trials

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05823480 2024-09-19

Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05367401 2024-04-11

A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT05720988 2024-03-08

Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia

Leukemia, Myeloid, Acute

NCT06180863 2023-12-26

Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT03932318 2023-07-20

Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients

Leukemia, Myeloid, Acute

NCT03745352 2023-06-27

Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Leukemia, Myeloid, Acute

NCT04230564 2023-06-07

Acute Myeloid Leukemia Real World Treatment Patterns

Withdrawn

Leukemia, Myeloid, Acute

NCT04296214 2021-07-09

Pharmacoeconomics in the Application of 5-azacitidine in the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia

Withdrawn

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04128020 2020-10-12

Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia

Leukemia, Myeloid, Acute

NCT03612739 2019-10-29

EPITHINK

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03699384 2019-02-20

Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT02204020 2018-03-30

UPCI 13-165

Graft vs Host Disease, Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT02829840 2017-06-02

Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02303782 2016-09-01

A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT)

Leukemia, Myeloid, Acute

NCT01067274 2015-12-30

ALFA-0703

Phase 3 Withdrawn